Mindset Pharma Inc. announced that the United States Patent and Trademark Office (USPTO) has granted allowance for another of Mindset's Family 1 patent applications, number 17/743,718, titled Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. Included in this patent are certain deuterated psilocybin analogs from Family 1. Family 1 consists of psilocybin-inspired drug candidates that demonstrate improved pharmacokinetic, efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies. This application is one of a family of applications having a priority date of February 4, 2020.
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |